Drug intelligence / Profile preview

KC1101

Development stage: Preclinical
Lead developer: Beijing Kangchen Biological Technology

Overview

KC1101 is an early-stage anti-tumor drug candidate under development by Beijing Kangchen Biological Technology (also known as Konruns). Currently in the preclinical or IND-enabling phase, the specific biological target and therapeutic modality of KC1101 have not yet been disclosed by the developer. It is being investigated for its potential application in the treatment of various cancers as part of the company's oncology pipeline.

Beyond the preview

Go deeper on KC1101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KC1101.

Explore the full profile